The whole-body scan company is launching a research network with 50+ institutions. Early findings come with some big open ...

The company added hormone therapy to its platform and released IBS results from nearly 16,000 members, with caveats attached.

All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is ...

Patent cliffs and falling R&D productivity push the biggest players toward other people's science – our report puts numbers ...

Monte Rosa’s NEK7-targeting drug pulled several heart-risk biomarkers toward healthy levels in 108 people with obesity.

A Lancet Neurology study of 130 blood proteins in patients receiving lecanemab suggests amyloid clearance and cognitive ...

Mighty Therapeutics and the University of Washington will use pilot data on elamipretide to design a larger trial in older ...

Lovehoney’s hormone-free MenoPulse device launches, pairing air-pulse tech with early data on symptoms and autonomic function ...

Forecast for rapid growth by 2033, with disease-modifying therapies driving sales – and healthcare systems confronting the cost of access.

Arvinas presented early biomarker data on ARV-102, an oral drug built to clear the LRRK2 protein, at a major Parkinson’s ...

Better U and Evernow have joined forces to pair menopause specialists with psychiatry in a nationwide telehealth service.

QIMA Life Sciences launches SQINGEVITY, bringing biological testing and clinical studies together to examine claims about ...